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Abstract
Sickle cell disease is the most common inherited hematologic disorder that leads to the irreversible
damage of multiple organs. Although sickling of red blood cells and vaso-occlusion are central to
the pathophysiology of sickle cell disease the importance of hemolytic anemia and vasculopathy
has been recently recognized. Hypercoagulation state is another prominent feature of sickle cell
disease and is mediated by activation of both intrinsic and extrinsic coagulation pathways.
Growing evidence demonstrates that coagulation may not only contribute to the thrombotic
complications, but also to vascular inflammation associated with this disease. This article
summarizes the role of vascular inflammation and coagulation activation, discusses potential
mechanisms responsible for activation of coagulation and reviews recent data demonstrating the
crosstalk between coagulation and vascular inflammation in sickle cell disease.
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Introduction
Sickle cell anemia is the most common and severe variant of sickle cell disease. It is a
hematologic disorder caused by a single nucleotide mutation that substitutes glutamic acid
with valine at the sixth position of the β-globin gene (Frenette and Atweh 2007, Hebbel, et
al 2009, Rees, et al 2010). Homozygosity for this mutation leads to abnormal
polymerization of hemoglobin tetramers within erythrocytes under hypoxic conditions.
Aggregation of abnormally large hemoglobin polymers results in the formation of sickled
red blood cells that are less flexible, adhere to the endothelium and are prone to hemolysis
(Frenette and Atweh 2007, Hebbel, et al 2009, Rees, et al 2010). Clinical manifestations of
sickle cell disease include recurrent painful crises, chronic hemolytic anemia, acute chest
syndrome, pulmonary hypertension, stroke, kidney failure, priapism, leg ulcers,
osteonecrosis and cardiac disease (Frenette and Atweh 2007, Hebbel, et al 2009, Rees, et al
2010). Sickling of red blood cells results in the two primary pathologic events in sickle cell
disease: vaso-occlusion mediated ischemia-reperfusion injury and hemolytic anemia. Both
of these are thought to lead to increased vascular inflammation and activation of coagulation
(Frenette and Atweh 2007, Hebbel, et al 2009, Rees, et al 2010). The interactions between
vascular inflammation and coagulation and the contribution of coagulation to the pathology
of sickle cell disease are the primary focus of this review.
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In order to study the complex disease pathology, mouse models of SCD were developed.
The first generation of mouse models of SCD were created by homozygous deletion of
mouse β-globin and addition of the human sickle β-globin (βS) gene; these HbS mice
develop mild to moderate anemia with almost none of the clinical manifestations of sickle
cell disease due to the lack of human α-globin and low βS expression (Beuzard 2008). To
address this issue, newer mouse models have been developed in which mouse α-globin and
β-globin genes are deleted. These and other mouse models are described in detail in a recent
review (Beuzard 2008).The Berkley (BERK) model are homozygous knockouts for α-globin
and β-globin, and express a transgene containing human α-globin and βS-globin, as well
as Gγ- and Aγ-globin to prevent erythrocyte sickling during gestation and fetal death (Paszty,
et al 1997). The Townes mouse model of SCD also involves homozygous deletion of mouse
α-globin and β-globin gene, and knock-in of a transgene containing human α-globin, Aγ-
globin, and either βS-globin or healthy βA-globin (Wu, et al 2006). Embryonic lethality is
prevented because mice express fetal Hb (HbF), which persists until approximately one
month of age when the switch to HbS is complete. The advantage to these mice is that
healthy AA mice can be generated as littermate controls with SS mice, by breeding
heterozygous βA/βS pairs. The BERK and Townes models of SCD have severe anemia,
leukocytosis and multi-organ damage consistent with the human pathology (Paszty, et al
1997, Wu, et al 2006).
The pathology of sickle cell disease
Vaso-occlusion and ischemia reperfusion injury
The primary pathological event in sickle cell disease is the sickling of red blood cells, which
adhere to both the vascular endothelium and white blood cells (Frenette and Atweh 2007,
Rees, et al 2010). Healthy mature red blood cells have low to nonexistent expression of
adhesion molecules on their surface. However, anemia stimulates the bone marrow to
release immature red blood cells (reticulocytes). These reticulocytes express high levels of
adhesion molecules such as α4β1 integrin and CD36, which facilitate interactions with
adhesion molecules on endothelial cells and leukocytes (Joneckis, et al 1993). It has been
reported that sickle red blood cells adhere to vascular cell adhesion molecule (VCAM) on
endothelial cells via interaction with α4β1 integrin (Ataga, et al 2008, Gee and Platt 1995).
The vascular endothelium is also activated in sickle cell disease, and its role in the pathology
of this disease has been extensively reviewed (Hebbel, et al 2004). There is up-regulation of
adhesion molecules, such as VCAM, P-selectin, and E-selectin, which bind adhesion
molecules on red blood cells and on polymorphonuclear lymphocytes (Hebbel, et al 2004).
Biomarkers of endothelial activation, such as soluble (s)VCAM, sE-selectin, and sP-selectin
are elevated in patients with sickle cell anemia compared to controls (Ataga, et al 2008,
Setty, et al 2012). Endothelial P-selectin interacts with P-selectin glycoprotein ligand 1
(PSGL-1) expressed on almost all hematopoietic cells (Luo, et al 2012), and also contributes
to the interaction of sickle red blood cells with the endothelium (Gutsaeva, et al 2011). Luo
and colleagues recently demonstrated that inhibition of PSGL-1 in sickle cell mice reduced
leukocyte adhesion and rolling, and markers of endothelial activation. PSGL-1 inhibition
also reduced inflammation and liver injury (Luo, et al 2012). Endothelial E-selectin interacts
with E-selectin ligand 1 (ESL-1) on activated leukocytes (Mohan, et al 2005) in sickle cell
patients, as described below. Activated PMNs can bind to red blood cells via interactions
between CD11b/CD18 with various receptors on red blood cells (Hofstra, et al 1996).
Indeed, red blood cells isolated from sickle cell patients are reported to adhere to PMNs and
activate the respiratory burst; dense red blood cells that had undergone repeated sickling
events were more adherent (Hofstra, et al 1996). Adherence was due in part to interactions
between integrins on red cells and PMNs (Hofstra, et al 1996). In the humanized Berkley
(BERK) mouse model of sickle cell disease, intravital microscopy revealed enhanced
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leukocyte rolling in sickle cell mice compared to controls after an inflammatory stimulus.
Interestingly, circulating sickle red blood cells adhered more frequently to leukocytes than
the endothelium (Turhan, et al 2002). Inhibition of leukocyte adhesion to the endothelium,
through the use of E-selectin and P-selectin knockout mice transplanted with sickle bone
marrow also reduced sickle red blood cell adhesion (Turhan, et al 2002). Furthermore, the
frequency of red blood cell-PMN interactions is highly elevated and blood flow in the
cremaster microcirculation is decreased in sickle cell mice compared to control (Hidalgo, et
al 2009). In E-selectin knockout mice that were transplanted with sickle cell bone marrow,
the frequency of red blood cell-PMN interactions decreased and blood flow in the
microcirculation was improved, suggesting that signaling from E-selectin to PMNs
contributes to red blood cell-PMN interactions (Hidalgo, et al 2009). Indeed, E-selectin was
demonstrated to promote increased expression and activity of CD11b/CD18 integrin on
PMNs from sickle cell mice (Hidalgo, et al 2009). The complex interactions between sickle
RBCs, leukocytes and endothelial cells involve multiple adhesion molecules (Figure 1). In
essence, these interactions result in recurrent vaso-occlusive events in postcapillary venules
that lead to cyclic ischemia-reperfusion injury in multiple organs (Frenette 2002, Hebbel, et
al 2009, Rees, et al 2010).
Ischemia-reperfusion injury activates xanthine oxidase leading to the production of free
radicals (O2− and H2O2), which incite oxidative stress in endothelial cells (Carden and
Granger 2000). Ischemia-reperfusion injury also enhances the expression of adhesion
molecules, such as VCAM, intercellular adhesion molecule (ICAM), P-selectin, and E-
selectin on endothelial cells. Moreover, oxidative stress stimulates the release of platelet
activating factor (PAF) and leukotriene B4 (LTB4) from endothelial cells and these in turn
stimulate expression of CD11b/CD18 and CD62L (L-selectin) on PMNs (Carden and
Granger 2000). Finally, activated PMNs and monocytes also contribute to oxidative stress in
sickle cell disease by generating reactive oxygen species during the respiratory burst
(Carden and Granger 2000, Hofstra, et al 1996).
Vascular inflammation
Patients with sickle cell anemia have chronic leukocytosis, particularly an increase in
monocytes and polymorphonuclear neutrophils (PMNs) (Qari, et al 2012, Vichinsky, et al
1997). Monocytes from sickle cell patients are highly activated, and express more
interleukin (IL)-1β and tumor necrosis factor (TNF)-α compared to monocytes from healthy
control subjects (Belcher, et al 2000, Wun, et al 2002). Interestingly, monocytes from sickle
cell patients can induce E-selectin, ICAM and VCAM expression on human endothelial cells
in culture (Belcher, et al 2000), indicating that endothelial cell-monocyte interactions are
highly interdependent. PMNs from sickle cell patients are also activated compared to control
subjects, marked by decreased surface CD62L expression and shedding of CD62L into the
plasma (Lard, et al 1999). Plasma levels of lactoferrin and elastase are also higher in sickle
cell patients, indicating degranulation of specific and azurophilic granules in PMNs,
respectively (Lard, et al 1999).
In addition to an activated endothelium and leukocytosis, the inflammatory phenotype of
sickle cell disease is also characterized by high levels of acute phase proteins and cytokines.
Sickle cell patients have higher levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β,
IL-6, IL-8, interferon (IFN)-γ, C-reactive protein (CRP), macrophage inflammatory protein
(MIP)-1α and monocyte chemotactic protein (MCP)-1 than healthy controls (Pathare, et al
2004, Qari, et al 2012). These inflammatory markers are chronically elevated in sickle
patients at “steady state”, and are often increased further after acute painful crises (Pathare,
et al 2004).
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Mouse models of sickle disease share this inflammatory phenotype. Belcher and colleagues
(Belcher, et al 2003) reported elevated levels of various inflammatory markers in four
transgenic mouse models of sickle cell disease (NY-S, Berkley-SAntilles, NY-S/SAntilles, and
Berkley- mice). All strains of sickle mice had leukocytosis, predominantly of neutrophils,
monocytes and lymphocytes. Furthermore, plasma levels of serum amyloid protein (SAP,
the murine analog of human CRP) and IL-6 were elevated. Additionally, there was an
enhanced expression of VCAM-1, ICAM-1 and platelet endothelial cell adhesion molecule
(PECAM) in the lungs of sickle mice compared to non-sickle controls. The expression of
these adhesion molecules was dependent on the transcription factor NF-κB (Belcher, et al
2003). We have recently confirmed these data in the Berkley mice and showed a similar pro-
inflammatory phenotype in the Townes mouse model of sickle cell disease. In addition, an
enhanced accumulation of neutrophils in the lung and liver, and increased expression of the
chemokines MCP-1 and KC was observed in sickle cell mice in both models
(Chantrathammachart, et al 2012a).
Hemolytic anemia and NO depletion
Other important components in sickle cell disease pathology are hemolytic anemia and
decreased nitric oxide (NO) bioavailability (Kato, et al 2007). Intravascular hemolysis
results in release of cell-free hemoglobin at a rate of up to 30 g per day, which then liberates
heme into the plasma. Plasma heme levels average 4.3 ± 1.1 μM in sickle cell patients,
whereas it is undetectable in healthy controls (Reiter, et al 2002). This excess amount of
hemoglobin and heme saturate their respective scavenging molecules, haptoglobin and
hemopexin (Reiter, et al 2002), the levels of which are decreased in sickle cell patients
(Muller-Eberhard, et al 1968). Hemoglobin and free heme consume NO to generate
methemoglobin and nitrate (Kato, et al 2007). The production of NO is also depleted in
sickle cell disease; sickle red blood cells release arginase, which degrades L-arginine, the
substrate for NO production by endothelial nitric oxide synthase (eNOS) (Kato, et al 2007,
Morris, et al 2005). Reactive oxygen species react with NO to produce peroxynitrite (ONOO
−) which nitrosylates various proteins causing their dysfunction (Kato, et al 2007). The loss
of NO in sickle cell disease impairs its homeostatic functions, such as vasodilation and
inhibition of platelet activation. Furthermore, NO plays an important role in regulating
endothelial cell activation and cytokine production (Reiter, et al 2002), both of which are
major contributors to the pathogenesis of sickle cell disease.
Free heme liberated from hemoglobin during hemolysis is also pro-inflammatory by directly
activating endothelial cells and macrophages. Heme induced TNF-α and keratinocyte
chemoattractant (KC) expression in macrophages depends on toll-like receptor 4 (TLR4)
signaling (Wagener, et al 2001). TLR-4 signaling has also been implicated in heme-
mediated acute lung injury in a sickle cell mouse model (Ghosh, et al 2011). Heme also
incites oxidative stress and heme oxygenase (HO)-1 expression in macrophages (Figueiredo,
et al 2007). Further, free heme can also contribute to vascular inflammation via endothelial
cell dysfunction and activation. Heme generates intracellular ROS and increased expression
of VCAM, ICAM and E-selectin on endothelial cells in vitro (Wagener, et al 1997).
Injection of heme also increases ICAM-1 expression in livers of mice, and leukocyte
migration into various tissues. In addition to upregulation of adhesion molecules and
chemokine production, heme can stimulate PMN migration by directly activating chemokine
receptors in vitro and in vivo (Porto, et al 2007). Furthermore, free heme activates
respiratory burst in PMNs (Porto, et al 2007).
Hypercoagulation and thrombosis in sickle cell disease
The coagulation cascade can be divided into the extrinsic, intrinsic and common pathways
(Mackman 2012, Pawlinski, et al 2004). The extrinsic pathway consists of the
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transmembrane receptor tissue factor (TF) and plasma factor VII/VIIa (FVII/FVIIa). TF
binds FVII/FVIIa and forms a TF:FVIIa complex that activates FX to FXa (Mackman 2012,
Pawlinski, et al 2004). The intrinsic pathway provides an alternative way to activate
coagulation via FXIIa and FXIa. It also amplifies the generation of FXa via the FVIIIa/FIXa
intrinsic tenase complex. Coagulation activation results in thrombin generation, fibrin
deposition and activation of platelets (Mackman 2012, Pawlinski, et al 2004).
Activation of coagulation in sickle cell disease has been well documented (Ataga 2009,
Ataga and Key 2007, De Franceschi, et al 2011). Excessive thrombin generation in sickle
cell patients is indicated by increased plasma levels of prothrombin fragment 1.2 (F1.2) and
thrombin anti-thrombin (TAT) complexes (Ataga, et al 2008, Peters, et al 1994, Stuart and
Setty 2001, van Beers, et al 2008). Higher thrombin peak height, higher rates of thrombin
formation, and higher endogenous thrombin potential has been reported in platelet-poor
plasma of sickle cell patients compared to age-matched controls using calibrated automated
thrombogram method of measuring thrombin generation (Noubouossie, et al 2011). In
addition, increased plasma levels of D-dimers, fibrinopeptide A, fibrin-fibrinogen peptide E
and plasmin-antiplasmin complexes indicate ongoing thrombin-dependent fibrinogen
cleavage, clot formation and subsequent fibrinolysis (Adam, et al 2009, Ataga, et al 2008,
Leslie, et al 1975, Tomer, et al 2001a, Tomer, et al 2001b, van Beers, et al 2008,
Westerman, et al 1999). Moreover, the levels of protein C and protein S are decreased in
patients with sickle cell disease, presumably due to increased consumption of these natural
anticoagulants (el-Hazmi, et al 1993, Francis 1988, Green and Scott 1986, Tam 1997,
Westerman, et al 1999). In contrast, plasma levels of tissue factor pathway inhibitor, a
natural inhibitor of TF, were not changed in sickle cell patients (Key, et al 1998). Finally,
patients with sickle cell disease have a propensity to develop thrombotic complications. In
situ thrombosis of small pulmonary vessels is a common finding during autopsy studies
(Adedeji, et al 2001, Kirkpatrick and Haynes 1994, Oppenheimer and Esterly 1971). The
incidence of inpatient pulmonary embolism is higher in the sickle cell disease population
than in the non- sickle cell disease population (Novelli, et al 2012). It has been shown that
sickle cell patients have a higher prevalence of pulmonary thrombosis but not deep vein
thrombosis compared to age- and race-matched controls, suggesting that pulmonary
thrombosis occurs as a primary rather than secondary embolic event in this disease (Stein, et
al 2006). However, a recent cross-sectional study demonstrated that sickle cell patients had
equally high rates of both deep venous thrombosis and pulmonary embolism. Importantly,
non catheter-related venous thromboembolism was an independent risk factor for death in
this cohort of patients. Mekontso Dessap and coworkers demonstrated pulmonary artery
thrombosis in a sickle cell patient during acute chest syndrome (Mekontso Dessap, et al
2011). Sickle cell disease is also a significant risk factor for pregnancy-related venous
thromboembolism (James, et al 2006). Furthermore, thrombosis has been reported within
the vena cava and hepatic vein of sickle cell patients (Ng and Ashari 2003, Singh, et al
2010). Clinical evidence also points to the role of thrombosis in triggering stroke (Hillery
and Panepinto 2004, Prengler, et al 2002). Ischemic stroke commonly occurs in sickle cell
patients, with a risk of 0.5 – 1% per year (Adams 2007); strokes are often precipitated by
painful crises, when markers of coagulation and inflammation are elevated (Prengler, et al
2002). Consistent with these clinical observations, we and others have shown that plasma
levels of thrombin-antithrombin complexes are also increased in mouse models of sickle cell
disease (Chantrathammachart, et al 2012a, Guo, et al 2008). Furthermore, microthrombi and
increased fibrin deposition were observed in multiple organs in sickle mice including lung,
liver, kidneys and brain (Guo, et al 2008, Trudel, et al 1994). Exposing sickle cell mice to
hypoxic conditions resulted in further increases in plasma TAT levels and thrombosis within
the pulmonary vasculature (de Franceschi, et al 2003, Guo, et al 2008). Interestingly, it was
recently reported that biomarkers of coagulation activation (TAT and D-dimer) correlated
with a history of stroke, retinopathy and acute chest syndrome in a cohort of 52 sickle cell
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disease patients (Ataga, et al 2012), indicating that coagulation might contribute to these
pathologies.
Activation of coagulation in sickle cell disease
The hypercoagulable state and thrombotic complications of sickle cell disease are well
documented (Ataga and Key 2007, De Franceschi, et al 2011, Singer and Ataga 2008), but
the stimulus for coagulation activation is yet to be determined. Potential causes of
coagulation activation in sickle cell disease are discussed below.
Increased TF expression
TF is the primary activator of the extrinsic coagulation pathway (Bach 1988, Edgington, et
al 1991). It is constitutively expressed by perivascular cells such as vascular smooth muscle
cells, adventitial fibroblasts, and pericytes. TF expressed by these cells is normally
sequestered from blood, and it forms a hemostatic envelope to reduce blood loss upon
vascular injury (Drake, et al 1989, Fleck, et al 1990, Mackman, et al 2007). In addition,
inducible TF expression is observed in vascular cells during many pathologic conditions,
including sickle cell disease (Mackman, et al 2007).
Sickle cell patients have increased TF expression on monocytes (Setty, et al 2012) with
elevated whole blood TF procoagulant activity (Key, et al 1998). Furthermore, circulating
endothelial cells isolated from sickle cell patients showed increased levels of TF mRNA,
antigen, and activity (Solovey, et al 1998). TF expression in whole blood and circulating
endothelial cells was similarly increased in patients in pain crisis and those with steady-state
disease (Key, et al 1998, Solovey, et al 1998). TF expression was also increased in
circulating monocytes and in the endothelium of the lung microvasculature in mouse models
of sickle cell disease (Solovey, et al 2004). Hypoxia/reoxygenation challenge further
increases TF staining in both cell types (Solovey, et al 2004). We have recently shown that
TF expression was also increased in neutrophils isolated from sickle cell mice
(Chantrathammachart, et al 2012a). It has been proposed that the interaction of TF-positive
neutrophils with endothelial cells is a critical step for initiating thrombosis in the mouse
cremaster arterioles in a laser injury model (Darbousset, et al 2012). Perivascular cells can
also be a source of TF contributing to the activation of coagulation as shown in a mouse
model of endotoxemia (Pawlinski, et al 2010). Endothelial cell injury and increased vascular
permeability observed in sickle cell disease can make perivascular TF accessible to
circulating clotting factors and activate coagulation (Ghosh, et al 2012, Polanowska-
Grabowska, et al 2010, Wallace, et al 2009). Importantly, we have demonstrated that
inhibition of TF in sickle mice (Berkley and Townes mice) reduces plasma levels of TAT to
the baseline levels observed in control mice, indicating a critical role of TF in activation of
coagulation (Chantrathammachart, et al 2012a). The relative contribution of different
cellular sources of TF to the activation of coagulation is currently being investigated in our
laboratory.
Sickle Red Blood Cells and Activation of Coagulation
In normal red blood cells, procoagulant anionic phospholipids, such as phosphatidylserine
(PS), are almost completely restricted to the inner leaflet of the membrane (Connor and
Schroit 1991). Repeated cycles of sickling result in increased exposure of PS on the surface
of sickle red blood cells (Franck, et al 1985). PS exposure increases procoagulant activity by
providing a negatively charged surface which facilitates assembly of the clotting cascade
components. This process is mediated via an electrostatic interaction between negatively
charged PS and positively charged γ-carboxyglutamic acid domains present in the clotting
proteins, including FVII, FIX, FX and prothrombin (Owens and Mackman 2011). Analysis
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of blood from sickle cell patients demonstrated a positive correlation between PS positive
red blood cells and prothrombin fragment 1.2, D-dimers, and plasmin-antiplasmin complex
(Setty, et al 2000, Setty, et al 2001). Interestingly, no positive correlation has been found
between PS positive platelets and these markers of coagulation activation, which suggests
that sickle red blood cells, rather than platelets, contribute to the hypercoagulable state in
sickle cell disease (Setty, et al 2001).
Circulating Microparticles
Microparticles (MPs) are small membrane vesicles released from activated or apoptotic
cells. The procoagulant properties of MPs are due to the presence of PS and TF on their
surface (Owens and Mackman 2011). Two recent papers demonstrated that MPs derived
from different cellular sources contribute to thrombin and fibrin generation via different
mechanisms (Aleman, et al 2011, Van Der Meijden, et al 2012). Platelet- and erythrocyte-
derived MPs, which are TF negative, failed to induce thrombin generation in FXII-deficient
plasma, and inhibition of FVII had no effect on thrombin generation (Van Der Meijden, et al
2012). The majority of circulating MPs in sickle cell patients originate from erythrocytes
and platelets (Allan, et al 1982, Wun, et al 1998). These MPs are TF negative and
demonstrate increased exposure of PS on their surface (Shet, et al 2003). Consistent with the
observation made by Van Der Meijden and coworkers, it has been shown that erythrocyte-
derived MPs isolated from the blood of sickle cell patients contribute to thrombin generation
via a FXI dependent but not FVII dependent mechanism (van Beers, et al 2009). In contrast,
thrombin generation induced by TF-positive monocyte-derived MPs requires FVII but not
FXII (Van Der Meijden, et al 2012). A recent study demonstrated that thrombospondin-1
mediated release of erythrocyte MPs facilitates endothelial cell injury and vaso-occlusion in
sickle cell mice (Camus, et al 2012). It has been shown that the blood of sickle cell patients
does contain a small fraction of monocyte- and endothelial cell-derived MPs, which have
been identified as TF positive (Shet, et al 2003). In contrast to this observation, a recent
study reported no evidence for the presence of TF positive MPs in sickle cell patients (van
Beers, et al 2009). Furthermore, Setty and coworkers demonstrated that MP-associated TF
procoagulant activity was not elevated in the plasma of young children with sickle cell
disease compared to age-matched controls, and MP-associated TF procoagulant activity did
not correlate with markers of coagulation activation (Setty, et al 2012). A similar lack of
correlation was observed in adult sickle cell patients (Ataga, et al 2012) and in our recent
mouse study (Chantrathammachart, et al 2012a). Together, these data suggest that in sickle
cell disease, MPs contribute to the activation of coagulation most likely via PS-dependent
mechanism that requires activation of the intrinsic coagulation pathway.
Platelets
A moderate increase in platelet numbers is observed in older children and adults with SCD
in steady state (Francis 1991). Circulating platelets in these patients are chronically activated
and platelet aggregation is increased (Kenny, et al 1980, Westwick, et al 1983). This may be
attributed to the increased numbers of young, metabolically active platelets or increased
plasma levels of platelets agonists, such as epinephrine, adenosine diphosphate or thrombin,
in the blood of sickle cell patients. Platelet levels of P-selectin and CD40 ligand are also
increased in sickle cell patients compared to healthy control subjects (Garrido, et al 2012,
Lee, et al 2006, Tomer, et al 2001a). An increased number of platelet-monocyte aggregates
has been observed in both sickle cell patients and a mouse model of sickle cell disease
(Polanowska-Grabowska, et al 2010). The formation of these aggregates was mediated via
platelet P-selectin (Polanowska-Grabowska, et al 2010). Interestingly, platelet P-selectin and
CD40 ligand have been shown to induce rapid expression of TF in monocytes (Lindmark, et
al 2000). Furthermore, inhibition of CD40 ligand receptor reduced monocyte TF expression
induced by the plasma from sickle cell patients (Lee, et al 2006). Platelets from sickle cell
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patients also express higher levels of the pro-inflammatory cytokine LIGHT (TNFSF14),
which promotes endothelial activation and inflammation (Garrido, et al 2012) and
demonstrated increased αIIbβ3-depenent adhesion to fibrinogen (Proenca-Ferreira, et al
2010). Therefore platelets might participate to vaso-occlusive events by binding at the site of
inflammation with consequent release of inflammatory mediators.
Ultralarge von Willebrand factor (vWF) multimers
Sickle cell patients demonstrate increased levels of circulating ultralarge vWF multimers in
their blood (Chen, et al 2011, Krishnan, et al 2008). This increase in ultralarge vWF
multimers can result from the combination of increased secretion, defective clearance, and
impaired cleavage by ADAMTS13. Recent studies demonstrate that impaired processing of
ultralarge vWF multimers by ADAMTS13 in sickle cell patients is not the result of
ADAMTS13 deficiency, but might reflect resistance of vWF to proteolysis. The resistance
could result from either the oxidation of Met1606 at the ADAMTS13 cleavage site, or the
binding of free hemoglobin to the A2-domain of vWF (Chen, et al 2010, Zhou, et al 2009).
Since a portion of ultralarge vWF multimers remains anchored to the endothelium upon
activation of endothelial cells (Dong, et al 2002), it is likely that the increase observed in
circulation reflects a similar increase in the endothelium-bound ultralarge vWF multimers in
sickle cell patients. It has been shown that ultralarge vWF multimers mediate the adhesion
of sickle red blood cells to the endothelium (Wick, et al 1987) and platelets aggregations
(Ruggeri 2007). Therefore, the endothelium-bound ultralarge vWF multimers may
contribute to both vaso-occlusion and generation of thrombogenic surface on the
endothelium in SCD.
Regulation of TF expression and activation of coagulation in sickle cell
disease
Several mouse studies have examined the mechanism and regulation of TF expression in
sickle cell disease. Using a bone marrow transplantation approach, Kollander and colleagues
demonstrated that endothelial TF expression is highly dependent on NF-κB(p50) in
peripheral blood mononuclear cells, but not in the vessel wall, of sickle cell mice
(Kollander, et al 2010). These data suggest that peripheral blood mononuclear cells
indirectly promote endothelial TF expression via a NF-κB(p50)-dependent mechanism.
An in vitro study demonstrated that heme, a product of intravascular hemolysis, induces the
expression of functionally active TF on both micro- and macro-vascular endothelial cells
(Setty, et al 2008). Consistent with these results, multiple regression analyses identified an
association between markers of hemolysis and markers of coagulation activation in sickle
cell patients (Setty, et al 2012). Recently, we have shown that heme can induce activation of
coagulation in mice in a TF-dependent manner (Sparkenbaugh, et al 2012). Endothelial
nitric oxide synthase (eNOS) negatively regulates endothelial cell TF expression via
generation of NO (Solovey, et al 2010). Consistent with that observation, inhalation of NO
attenuated increased endothelial TF expression and reduced the number of thrombi in small
lung vessels in sickle mice subjected to hypoxia/reoxygenation injury (de Franceschi, et al
2003, Solovey, et al 2010). Furthermore, lovastatin treatment also reduced the increased TF
staining observed in pulmonary endothelial cells of sickle cell mice (Solovey, et al 2004).
Interestingly, lovastatin treatment in sickle cell mice did not attenuate inducible TF
expression in monocytes or constitutive TF expression in perivascular cells (Solovey, et al
2004). However, a short term use of simvastatin had only a modest effect on plasma levels
of TF antigen in sickle cell patients (Hoppe, et al 2011). In addition, the histone deacetylase
inhibitors trichostatin A and suberoylanilide hydroxamic acid also reduced endothelial TF
expression in Berkley mice after a hypoxia/reoxygenation challenge (Hebbel, et al 2010).
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The reduction may result from either direct inhibition of TF expression (Wang, et al 2007)
or could be an indirect result of the increased expression of fetal hemoglobin and overall
attenuation of disease severity (Bradner, et al 2010, Sangerman, et al 2006).
Finally, hydroxyurea treatment has been shown to reduce many markers of coagulation
activation. A recent study by Colella and colleagues showed that sickle cell patients on
hydroxyurea treatment had significant reduction in leukocyte TF mRNA expression, plasma
levels of TF protein, as well as plasma levels of F1.2 fragments and TAT complexes
(Colella, et al 2012). Treatment with hydroxyurea was also associated with a decrease in the
formation of red blood cell derived PS-positive MPs and subsequent attenuation of thrombin
generation (Gerotziafas, et al 2012). Coincidentally, hydroxyurea therapy is also associated
with decreased mortality and morbidity, reduced painful crises and chest syndrome
(Steinberg, et al 2003), and fewer vaso-occlusive events (Charache, et al 1995).
Contribution of coagulation to the pathology of sickle cell disease
Several clinical studies have investigated the effect of different antiplatelet and
anticoagulant agents in sickle cell disease. The thromboxane inhibitor aspirin or the ADP
receptor antagonist ticlopidine had either modest or no effects on the duration or frequency
of acute pain crisis in sickle cell patients (Cabannes, et al 1984, Chaplin, et al 1980,
Greenberg, et al 1983, Osamo, et al 1981, Semple, et al 1984, Zago, et al 1984). Recently, a
small phase 1 study demonstrated that the platelet inhibitor prasugrel significantly reduced
ex vivo platelet reactivity and was well tolerated in sickle cell patients (Jakubowski, et al
2012). The impact of anticoagulation on the frequency or severity of vaso-occlusive events
has been investigated using warfarin, acenocoumarol or heparins (Chaplin, et al 1989,
Salvaggio, et al 1963, Schnog, et al 2001, Wolters, et al 1995). Most of these studies were
not randomized, and were performed on a small number of patients. They demonstrated
modest effects at best. Notably, the only adequately powered and placebo-controlled study
examining the effect of low molecular weight heparin in sickle cell disease showed a
significant reduction in the duration of pain crisis and time of hospitalization (Qari, et al
2007). However it is difficult to say if the protective effects were mediated by anticoagulant
properties of low molecular weight heparin, or resulted from the inhibition of P-selectin-
mediated cellular interactions (Kutlar, et al 2012, Matsui, et al 2002). Since all of the
clinical studies investigating the role of anticoagulation in sickle cell disease focused
primarily on the frequency or severity of vaso-occlusive events, it is still unknown if
activation of coagulation contributes to the pathology of sickle cell disease or is just a
secondary event. Some insight into that question comes from the recent studies using mouse
models of sickle cell disease. Guo and co-workers demonstrated that the treatment of
Berkley mice with enoxaparin for two weeks not only reduced vascular congestion in the
lung but also attenuated endothelial cell injury measured by plasma levels of sVCAM-1
(Guo, et al 2010). The same group showed that a genetic deficiency of TF in non-
hematopoietic cells reduces vascular congestion in the livers of sickle cell mice (Hillery, et
al 2004). Inhibition of TF or thrombin also attenuated the enhanced thrombosis in cerebral
microvessels of mice expressing the sickle form of hemoglobin (Gavins, et al 2011).
Importantly, we have demonstrated that TF not only promotes activation of coagulation but
also contributes to vascular inflammation in two mouse models of sickle cell disease
(Berkley and Townes mice) (Chantrathammachart, et al 2012a). Inhibition of TF reduced
leukocytosis and attenuated plasma levels of IL-6, SAP and sVCAM-1. In addition, TF
inhibition also reduced expression of MPO and chemokines MCP-1 and KC in the lungs of
Berkley mice. Furthermore, TF inhibition had no effect on plasma intravascular hemolysis,
indicating that TF contributes to the vascular inflammation downstream of intravascular
hemolysis (Chantrathammachart, et al 2012a) (Figure 2). It is still unclear if the TF:FVIIa
complex promotes inflammation in sickle cell disease directly or via generation of
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downstream coagulation proteases. We have shown that endothelial cell-specific deletion of
the TF gene reduced plasma levels of IL-6 but not TAT (Chantrathammachart, et al 2012a).
This intriguing observation strongly suggests that endothelial cell TF contributes to the
expression of IL-6 independent of thrombin generation, most likely via FVIIa– and/or FXa–
dependent activation of protease-activated receptor-2 (PAR-2) (Camerer, et al 2000, Rao
and Pendurthi 2005). TF/FVIIa–dependent activation of PAR-2 has been shown to promote
inflammation in various mouse models (Badeanlou, et al 2011, Redecha, et al 2008).
Furthermore, we have observed attenuation of vascular inflammation, including reduction of
plasma levels of IL-6, in sickle cell mice lacking PAR-2 in all non-hematopoietic cells
(Chantrathammachart, et al 2012b).
Little is known about the contribution of downstream coagulation proteases and fibrinogen
to the pathology of sickle cell disease. Inhibition of thrombin abrogated microvascular
thrombosis in mice expressing the sickle form of human β-globin. In addition, platelets
isolated from these mice exhibited enhanced aggregation after stimulation with thrombin but
not ADP (Gavins, et al 2011). PAR-1 is the main thrombin receptor. Injection of a PAR-1
agonist peptide into sickle cell mice increased the expression of endothelial P-selectin and
reduced microvascular blood flow by enhancing the adhesion of red blood cells to the
endothelium (Embury, et al 2004). Surprisingly, a complete deficiency in fibrinogen was
associated with increased mortality in the milder mouse model of SCD (SAD mice)
(Roszell, et al 2007).The authors did not investigate the mechanism underlying this
observation. However, the pathologic effects of fibrinogen deficiency observed in sickle cell
mice may be due to an exacerbation of EC injury caused by increased thrombin signaling.
Supporting this hypothesis, sickle cell mice lacking fibrinogen demonstrated increased
plasma levels of TAT and sVCAM-1 (Hillery, et al 2004). Increased levels of circulating
thrombin are also observed in patients with afibrinogenemia (Dupuy, et al 2001). Further
studies are needed to investigate the mechanism by which TF and downstream coagulation
proteases, including FXa and thrombin, contribute to vascular inflammation. Possible
mechanisms may involve coagulation protease-dependent activation of PARs as well as
thrombin-dependent fibrin generation which contributes to local tissue inflammation via
activation of leukocytes and promoting infiltration of these cells into inflamed tissues
(Figure 3) (Flick, et al 2004a, Flick, et al 2004b, Petzelbauer, et al 2005).
Conclusions
Complex interactions between sickle red cells, leukocytes and endothelial cells lead to vaso-
occlusive crises, recurring episodes of ischemia-reperfusion injury and chronic hemolysis. It
is evident that these processes are highly interdependent, can influence one another and lead
to multiple pathologic manifestations of sickle cell disease, including vascular inflammation
and activation of coagulation (Belcher, et al 2000, Hidalgo, et al 2009, Wun, et al 2002).
Hypercoagulation is a prominent feature of sickle cell disease and leads to the prothrombotic
complications in sickle cell patients. Activation of both extrinsic and intrinsic coagulation
pathways contributes to the procoagulant state associated with this disease and is mediated
by increased TF expression and increased PS exposure. Given the chronic activation of
coagulation and our recent data demonstrating cross-talk between coagulation and
inflammation in mouse models of sickle cell disease, further and more definitive evaluation
of the potential therapeutic benefit of anticoagulants in sickle cell patients is warranted.
More studies are necessary to determine the optimal target(s) in the coagulation and PAR-
dependent signaling pathways, defined as that which will maximally inhibit coagulation and
vascular inflammation while minimally predisposing patients to complications, such as
bleeding. These studies should pave the way to the design of future trials examining the
effect of anti-coagulant treatment on clinically relevant endpoints in SCD, such as
vasoocclusive crisis, venous thromboembolism and pulmonary hypertension. The new oral
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anticoagulants targeting FXa or thrombin, which have been recently approved for clinical
use (Eikelboom and Weitz 2010), provide a potential starting point for these studies.
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Interactions between sickle RBCs, leukocytes and endothelial cells are mediated by multiple
adhesion molecules.
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Figure 2. Cross-talk between coagulation and vascular inflammation in SCD
Vaso-occlusion (VOC) and hemolysis-dependent endothelial cell (EC) activation and
inflammation lead to the increased expression of tissue factor (TF) by various cell types,
phosphatidylserine exposure and subsequent activation of coagulation. We propose that
activation of coagulation creates a positive feed-back loop that further enhances VOC, EC
activation and inflammation via protease activated receptors (PARs) and thrombosis
dependent mechanisms.
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Proposed mechanism by which TF, FXa and thrombin contribute to the pathology of SCD.
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